SNY - Investor Demand for Clarity Grows Amid Sanofi's Strategic R&D Shift | Benzinga
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget.
In October, the company redirected funds towards testing new immunology and inflammation drugs in an unexpected shift in its strategy.
Hudson's decision to abandon 2025 margin targets to fortify the drug pipeline sparked concerns among investors, overshadowing the company's proposed